RT Journal Article
SR Electronic
T1 Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.12.20211599
DO 10.1101/2020.10.12.20211599
A1 Martin Dugas
A1 Tanja Grote-Westrick
A1 Richard Vollenberg
A1 Eva Lorentzen
A1 Tobias Brix
A1 Hartmut Schmidt
A1 Phil-Robin Tepasse
A1 Joachim Kühn
YR 2020
UL http://medrxiv.org/content/early/2020/10/14/2020.10.12.20211599.abstract
AB The clinical course of COVID-19 is very heterogeneous: Most infected individuals can be managed in an outpatient setting, but a substantial proportion of patients requires intensive care, resulting in a high rate of fatalities. Recently, an association between contact to small children and mild course of COVID-19 was reported. We performed an observational study to assess the impact of previous infections with seasonal coronaviruses on COVID-19 severity. 60 patients with confirmed COVID-19 infections were included (age 30 - 82 years; 52 males, 8 females): 19 inpatients with critical disease, 16 inpatients with severe or moderate disease and 25 outpatients (age and gender matched to inpatients). Patients with critical disease had significantly lower levels of HCoV OC43- (p=0.016) and HCoV HKU1-specific (p=0.023) antibodies at the first encounter compared to other COVID-19 patients. Our results indicate that previous infections with seasonal coronaviruses might protect against a severe course of disease. This finding should be validated in other settings and could contribute to identify persons at risk before an infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by a grant from BMBF (HiGHmed 01ZZ1802V, Use Case Infection Control). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:local ethics committee approval: AZ 2020-220-f-S and AZ 2020-210-f-SAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to data protection regulations, personal identifiable data cannot be published.